AIM
GMAB icon

Advyzon Investment Management’s Genmab GMAB Stock Holding History

Advyzon Investment Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,239
Closed -$469K – 697
2025
Q4 		$469K Buy
15,239
+8,201
+117% +$256K 0.05% 337
2025
Q3 		$216K Buy
+7,038
New +$172K 0.04% 430

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Advyzon Investment Management's GMAB Position: Q1 2026 in Review

Advyzon Investment Management sold out of Genmab (GMAB) in Q1 2026, closing a stake of 15,239 shares — an estimated $469K sold.

Advyzon Investment Management first reported a position in GMAB in Q3 2025 and held it in 2 quarters. The position peaked at $469K in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Advyzon Investment Management reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Advyzon Investment Management sold 15,239 Genmab shares in Q1 2026, an estimated $469K.
  • Advyzon Investment Management first reported a position in Genmab in Q3 2025 and held it in 2 quarters.
  • Advyzon Investment Management's Genmab position peaked at $469K in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Advyzon Investment Management's 13F filing for Q1 2026, filed 12 May 2026.